Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul 3;6(7):e2321730.
doi: 10.1001/jamanetworkopen.2023.21730.

Baseline Features and Reasons for Nonparticipation in the Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Study, a Colorectal Cancer Screening Trial

Douglas J Robertson  1   2 , Jason A Dominitz  3   4 , Alexander Beed  5 , Kathy D Boardman  6 , Barbara J Del Curto  6 , Peter D Guarino  7 , Thomas F Imperiale  8 , Andrew LaCasse  1 , Meaghan F Larson  3 , Samir Gupta  9 , David Lieberman  10 , Beata Planeta  5 , Aasma Shaukat  11 , Shanaz Sultan  12 , Stacy B Menees  13   14 , Sameer D Saini  15   16   17 , Philip Schoenfeld  18 , Stephan Goebel  19   20 , Erik C von Rosenvinge  21   22 , Gyorgy Baffy  23 , Ildiko Halasz  23   24 , Marcos C Pedrosa  23   25 , Lyn Sue Kahng  26 , Riaz Cassim  27   28 , Katarina B Greer  29   30 , Margaret F Kinnard  29   31 , Divya B Bhatt  32 , Kerry B Dunbar  33 , William V Harford Jr  32 , John A Mengshol  34 , Jed E Olson  35 , Swati G Patel  36 , Fadi Antaki  37 , Deborah A Fisher  38 , Brian A Sullivan  39   40 , Christopher Lenza  41 , Devang N Prajapati  42 , Helen Wong  42 , Rebecca Beyth  43 , John G Lieb 2nd  44   45 , Joseph Manlolo  46 , Fernando V Ona  47 , Rhonda A Cole  48 , Natalia Khalaf  49   50 , Charles J Kahi  51 , Divyanshoo Rai Kohli  52   53 , Tarun Rai  54 , Prateek Sharma  55   56 , Jiannis Anastasiou  57 , Curt Hagedorn  58 , Ronald S Fernando  59   60 , Christian S Jackson  59   60 , M Mazen Jamal  60   61 , Robert H Lee  62   63 , Farrukh Merchant  64 , Folasade P May  65   66 , Joseph R Pisegna  67   68 , Endashaw Omer  69   70 , Dipendra Parajuli  70   71 , Adnan Said  72   73 , Toan D Nguyen  74   75 , Claudio Ruben Tombazzi  74   76 , Paul A Feldman  77 , Leslie Jacob  77 , Rachel N Koppelman  77 , Kyle P Lehenbauer  78 , Deepak S Desai  79 , Mohammad F Madhoun  80   81 , William M Tierney  80 , Minh Q Ho  82 , Heather J Hockman  45 , Christopher Lopez  83 , Emily Carter Paulson  84   85 , Martin Tobi  86 , Hugo L Pinillos  87   88 , Michele Young  41 , Nancy C Ho  10 , Ranjan Mascarenhas  89   90 , Kirrichai Promrat  91   92 , Pritesh R Mutha  93 , William M Pandak Jr  94   95 , Tilak Shah  96 , Mitchell Schubert  95   97 , Frank S Pancotto  98   99 , Andrew J Gawron  100   101 , Amelia E Underwood  100 , Samuel B Ho  102 , Priscilla Magno-Pagatzaurtundua  103 , Doris H Toro  103 , Charles H Beymer  104   4 , Andrew M Kaz  4   105 , Jill Elwing  106   107 , Jeffrey A Gill  108   109 , Susan F Goldsmith  108 , Michael D Yao  110   111 , Petr Protiva  112   113 , Heiko Pohl  1   2 , Tassos Kyriakides  5 ; CONFIRM Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Baseline Features and Reasons for Nonparticipation in the Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Study, a Colorectal Cancer Screening Trial

Douglas J Robertson et al. JAMA Netw Open. .

Erratum in

  • Error in Byline.
    [No authors listed] [No authors listed] JAMA Netw Open. 2023 Aug 1;6(8):e2330304. doi: 10.1001/jamanetworkopen.2023.30304. JAMA Netw Open. 2023. PMID: 37566425 Free PMC article. No abstract available.

Abstract

Importance: The Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) randomized clinical trial sought to recruit 50 000 adults into a study comparing colorectal cancer (CRC) mortality outcomes after randomization to either an annual fecal immunochemical test (FIT) or colonoscopy.

Objective: To (1) describe study participant characteristics and (2) examine who declined participation because of a preference for colonoscopy or stool testing (ie, fecal occult blood test [FOBT]/FIT) and assess that preference's association with geographic and temporal factors.

Design, setting, and participants: This cross-sectional study within CONFIRM, which completed enrollment through 46 Department of Veterans Affairs medical centers between May 22, 2012, and December 1, 2017, with follow-up planned through 2028, comprised veterans aged 50 to 75 years with an average CRC risk and due for screening. Data were analyzed between March 7 and December 5, 2022.

Exposure: Case report forms were used to capture enrolled participant data and reasons for declining participation among otherwise eligible individuals.

Main outcomes and measures: Descriptive statistics were used to characterize the cohort overall and by intervention. Among individuals declining participation, logistic regression was used to compare preference for FOBT/FIT or colonoscopy by recruitment region and year.

Results: A total of 50 126 participants were recruited (mean [SD] age, 59.1 [6.9] years; 46 618 [93.0%] male and 3508 [7.0%] female). The cohort was racially and ethnically diverse, with 748 (1.5%) identifying as Asian, 12 021 (24.0%) as Black, 415 (0.8%) as Native American or Alaska Native, 34 629 (69.1%) as White, and 1877 (3.7%) as other race, including multiracial; and 5734 (11.4%) as having Hispanic ethnicity. Of the 11 109 eligible individuals who declined participation (18.0%), 4824 (43.4%) declined due to a stated preference for a specific screening test, with FOBT/FIT being the most preferred method (2820 [58.5%]) vs colonoscopy (1958 [40.6%]; P < .001) or other screening tests (46 [1.0%] P < .001). Preference for FOBT/FIT was strongest in the West (963 of 1472 [65.4%]) and modest elsewhere, ranging from 199 of 371 (53.6%) in the Northeast to 884 of 1543 (57.3%) in the Midwest (P = .001). Adjusting for region, the preference for FOBT/FIT increased by 19% per recruitment year (odds ratio, 1.19; 95% CI, 1.14-1.25).

Conclusions and relevance: In this cross-sectional analysis of veterans choosing nonenrollment in the CONFIRM study, those who declined participation more often preferred FOBT or FIT over colonoscopy. This preference increased over time and was strongest in the western US and may provide insight into trends in CRC screening preferences.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Robertson reported receiving advisory board fees from Freenome outside the submitted work. Dr Gupta reported receiving research support from Freenome and Epigenomics and consulting fees from Guardant Health, Geneoscopy, and InterVenn Bioscience outside the submitted work. Dr Lieberman reported receiving consulting fees from Geneoscopy outside the submitted work. Drs Schoenfeld and Antaki and Dr S. Ho reported receiving grants from the Department of Veterans Affairs (VA) during the conduct of the study. Drs Pedrosa, Kinnard, and Dunbar reported receiving grants from the VA Cooperative Study Program during the conduct of the study. Dr Sullivan reported receiving grants from Exact Sciences outside the submitted work. Dr Kohli reported receiving grants from Olympus Corporation of the Americas paid to his institution, standards of practice committee membership with the American Society for Gastrointestinal Endoscopy, and governance board membership with the American Board of Internal Medicine outside the submitted work. Prof Sharma reported receiving consulting fees from Olympus Corporation, Boston Scientific, Salix Pharmaceuticals, Cipla, Medtronic, Takeda, Samsung Bioepis, and CDx and grants from Erbe and Fujifilm outside the submitted work. Dr May reported receiving personal fees from Exact Sciences and Freenome outside the submitted work. Dr Pisegna reported receiving personal fees from AbbVie outside the submitted work. Dr Pohl reported receiving grants from Steris and Cosmo Pharmaceuticals and consulting fees from InterVenn Bioscience outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Flow Diagram Describing the Screened, Enrolled, and Randomized Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer Population
FIT indicates fecal immunochemical testing.
Figure 2.
Figure 2.. Individuals Eligible for Participation Who Declined Because of a Stated Preference for Stool Testing With Fecal Occult Blood Test or Fecal Immunochemical Test vs Colonoscopy, Stratified by Region and Year of Attempted Recruitment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi: 10.3322/caac.21708 - DOI - PubMed
    1. Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. Gastroenterology. 2020;158(2):418-432. doi: 10.1053/j.gastro.2019.06.043 - DOI - PubMed
    1. Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2022;162(1):285-299. doi: 10.1053/j.gastro.2021.10.007 - DOI - PubMed
    1. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153(1):307-323. doi: 10.1053/j.gastro.2017.05.013 - DOI - PubMed
    1. Davidson KW, Barry MJ, Mangione CM, et al. ; US Preventive Services Task Force . Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977. doi: 10.1001/jama.2021.6238 - DOI - PubMed

Publication types